Company Profile
Avalo Therapeutics Stock Price, News & Catalysts
- Ticker:
- AVTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
6.63 USD (-6.22%)
Close
Last updated: November 5, 2026
734M USD
Market cap
Why the stock is moving
Following the latest company update, “Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates”, AVTX closed down 6.22% at $6.63 on Nov 5, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Clinical Immunology Company
Avalo Therapeutics develops therapies for immune-mediated inflammatory diseases.
Abdakibart
Abdakibart is an antibody targeting IL-1β and is being developed for moderate-to-severe hidradenitis suppurativa.
LOTUS Evidence
The Phase 2 LOTUS study met its primary endpoint at both evaluated doses, supporting advancement into registrational development.
Future catalysts
- Avalo plans to advance abdakibart into a Phase 3 registrational program in hidradenitis suppurativa.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Avalo Therapeutics (AVTX)?
Avalo Therapeutics (AVTX) most recently closed at 6.63 USD, a -6.22% move versus the previous session.
What is the market cap of Avalo Therapeutics (AVTX)?
Avalo Therapeutics currently has a market capitalization of 734M USD on BioPharmSignal.
What does Avalo Therapeutics do?
Clinical Immunology Company Avalo Therapeutics develops therapies for immune-mediated inflammatory diseases. Abdakibart Abdakibart is an antibody targeting IL-1β and is being developed for moderate-to-severe hidradenitis suppurativa. LOTUS Evidence The Phase 2 LOTUS study met its primary endpoint at both evaluated doses, supporting advancement into...
On which exchange is AVTX stock listed?
Avalo Therapeutics (AVTX) is associated with NASDAQ, United States, Biopharma.
What is IL-1?
Abdakibart Abdakibart is an antibody targeting IL-1β and is being developed for moderate-to-severe hidradenitis suppurativa.
Which conditions is Avalo Therapeutics targeting with IL-1?
Avalo Therapeutics is associated with immunology based on its company overview and current catalyst commentary.
How does Avalo Therapeutics describe recent progress with IL-1?
Avalo plans to advance abdakibart into a Phase 3 registrational program in hidradenitis suppurativa.
What is Clinical?
Clinical Immunology Company Avalo Therapeutics develops therapies for immune-mediated inflammatory diseases.